O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 10.8 GBX 2.86%
Market Cap: 47.9m GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+66%
Revenue
Forecast
+447%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

OBI Price Targets Summary
Ondine Biomedical Inc

Wall Street analysts forecast OBI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OBI is 56.1 GBX with a low forecast of 55.55 GBX and a high forecast of 57.75 GBX.

OBI Lowest Forecast
Wall Street Target
55.55 GBX
414% Upside
OBI Average Forecast
Wall Street Target
56.1 GBX
419% Upside
OBI Highest Forecast
Wall Street Target
57.75 GBX
435% Upside
Lowest
Price Target
55.55 GBX
414% Upside
Average
Price Target
56.1 GBX
419% Upside
Highest
Price Target
57.75 GBX
435% Upside
Ondine Biomedical Inc Competitors:
Price Targets
IDXX
IDEXX Laboratories Inc
1% Upside
BSX
Boston Scientific Corp
20% Upside
S
STXS
Stereotaxis Inc
118% Upside
SRT
Sartorius AG
77% Upside
IDXX
IDEXX Laboratories Inc
1% Upside
BSX
Boston Scientific Corp
20% Upside
S
STXS
Stereotaxis Inc
118% Upside
SRT
Sartorius AG
77% Upside
ISRG
Intuitive Surgical Inc
16% Upside
6869
Sysmex Corp
33% Upside
METN
Metall Zug AG
3% Upside
EW
Edwards Lifesciences Corp
10% Upside

Revenue
Forecast

Revenue Estimate
Ondine Biomedical Inc

For the last 2 years the compound annual growth rate for Ondine Biomedical Inc's revenue is -32%. The projected CAGR for the next 4 years is 136%.

-32%
Past Growth
136%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ondine Biomedical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ondine Biomedical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
OBI intrinsic value, competitors valuation, and company profile.
DCF Valuation
OBI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OBI stock valuation using valuation multiples.
Wall Street Estimates
OBI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OBI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OBI's stock price target?
Price Target
56.1 GBX

According to Wall Street analysts, the average 1-year price target for OBI is 56.1 GBX with a low forecast of 55.55 GBX and a high forecast of 57.75 GBX.

What is Ondine Biomedical Inc's Revenue forecast?
Projected CAGR
136%

For the last 2 years the compound annual growth rate for Ondine Biomedical Inc's revenue is -32%. The projected CAGR for the next 4 years is 136%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.